@article{f0d937038207432eb34ee1ab331bb54d,
title = "CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab",
author = "Murtaza Khan and Ney, {Douglas E.} and Kleinschmidt-DeMasters, {Bette K.} and Lindsay Horton and Enrique Alvarez and Piquet, {Amanda L.}",
note = "Funding Information: M. Khan reports no disclosures. D.E. Ney received honoraria from consulting on DSMB for DNAtrix, Inc. B.K. Kleinschmidt-DeMasters and L. Horton report no disclosures. E. Alvarez has received research grants from Acorda, Biogen, Novartis, and Rocky Mountain MS Center and consulting honoraria from Actelion, Biogen, Celgene, Genentech, Genzyme, Teva, Novartis, and TG Therapeutics. A.L. Piquet has received research funding from the Drake Family. Outside of this work, Dr. Piquet reports honorarium from MedLink and consulting honoraria for serving on a scientific advisory board from Sanofi Gen-zyme. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.",
year = "2019",
month = jun,
day = "1",
doi = "10.1212/CPJ.0000000000000639",
language = "English (US)",
volume = "9",
pages = "273--276",
journal = "Neurology: Clinical Practice",
issn = "2163-0402",
publisher = "Lippincott Williams and Wilkins",
number = "3",
}